Takeda/Affymax's Hematide moves forward in Japan
19 February 2010
Ian Haydock
Please Login to read the full article.
19 February 2010
Ian Haydock
ian.haydock@informa.com
Takeda has begun a Phase III clinical trial in Japan with Affymax's erythropoiesis-stimulating agent (ESA) Hematide, marking progress in what could become a major market for the synthetic peptide product.
The study will recruit around 350 patients with anaemia related to chronic renal failure,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Concerns dampen Chugai's hopes for Epogin in chemotherapy-induced anaemia
- Safety concerns delay Epogin's Japanese approval for chemotherapy-induced anaemia
- Japanese recommendation moves edoxaban closer to first approval
- New data should provide reassurance over peginesatide's CV safety
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
